Delcath Systems (DCTH) Expected to Post Earnings on Tuesday

Delcath Systems (NASDAQ:DCTH) will likely be issuing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Delcath Systems to post earnings of ($0.10) per share and revenue of $26.00 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.16. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The firm had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. On average, analysts expect Delcath Systems to post ($0.17) EPS for the current fiscal year and $0.12 EPS for the next fiscal year.

Delcath Systems Stock Performance

Shares of DCTH stock opened at $14.51 on Tuesday. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $17.42. The stock has a market cap of $503.50 million, a price-to-earnings ratio of 1,452.45 and a beta of 0.60. The firm has a fifty day moving average of $15.85 and a 200-day moving average of $12.25.

Analyst Ratings Changes

DCTH has been the topic of several recent research reports. Weiss Ratings upgraded shares of Delcath Systems from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, October 13th. Zacks Research lowered shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. HC Wainwright restated a “buy” rating and set a $32.00 price target (up from $30.00) on shares of Delcath Systems in a research note on Friday, August 7th. Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, BTIG Research lifted their price objective on Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.50.

Delcath Systems Company Profile

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.